查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1853446

肝癌诊断市场按分期、最终用户、检测类型和技术划分－2025-2032年全球预测

Liver Cancer Diagnostics Market by Disease Stage, End User, Test Type, Technology - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，肝癌诊断市场规模将达到 169.7 亿美元，复合年增长率为 6.76%。

主要市场统计数据
基准年 2024 100.5亿美元
预计年份：2025年 107.3亿美元
预测年份：2032年 169.7亿美元
复合年增长率 (%) 6.76%

本文简要概述了正在重塑肝癌诊疗路径和相关人员优先事项的临床、技术和政策驱动因素的变化。

由于技术创新、临床实践的转变以及政策动态的变化，肝癌诊断领域正在迅速发展。本执行摘要了影响诊断路径、诊断方式选择和相关人员决策的最重要进展。接下来的章节将全面分析临床趋势、监管影响、技术成熟度和营运限制，从而阐明诊断领域相关人员的竞争格局和临床现状。

本分析旨在提供实用的综合分析，以支援产品开发、商业营运和医疗系统实施等各环节的策略规划。它重点关注多模态诊断方法如何融入诊疗路径、实证医学如何加速其应用，以及支付方的考虑如何影响医疗服务提供者的采纳。本节着重阐述诊断灵敏度和特异性要求、微创检测的需求以及早期发现以进行治疗干预的驱动力之间的相互关係，从而为更深入的分析奠定基础。

本报告优先考虑临床策略、监管事务、报销计划和商业开发相关人员的理解和需求。过渡性说明结合了生物标记科学和成像技术的发展趋势以及实验室运作和门诊诊断的实际考量，为后续更详细的专题和区域分析奠定了基础。

分子诊断、影像学和便于支付的证据生成方面的创新如何改变肝癌诊断管道

一系列变革性变化正在重塑肝癌的检测、鑑别和治疗方式。分子诊断和高灵敏度影像技术的进步使临床医生能够更早掌握疾病进展，减少对侵入性检查的依赖，同时提高肿瘤鑑别的精细度。同时，循环肿瘤DNA和微型RNA检测与现有的蛋白质标记的整合，正在推动混合诊断策略的发展，从而在不同的临床环境中平衡灵敏度和可操作性。

监管和报销框架正在根据真实世界数据和前瞻性检验研究产生的证据进行调整，从而在临床效用得到证实后加速推广应用。医疗服务提供者越来越多地采用多模态诊断演算法，将影像学方法与标靶生物标记组合相结合，以辅助治疗分层。同时，实验室工作流程的创新和分散式检查模式也促进了这一转变，扩大了门诊和诊断中心的可近性。

最后，次世代定序平台、先进生物资讯学和高解析度影像技术的融合，为精准诊断铺平了道路，从而指导个人化治疗方案的选择。这些转变降低了诊断的不确定性，缩短了确诊时间，并为肿瘤内科医生、介入放射科医生和多学科肿瘤委员会提供了更多可操作的数据。

评估近期关税调整如何再形成诊断服务和技术领域的筹资策略、供应商选择和资本配置决策。

2025年关税及贸易政策调整的实施，为诊断耗材、影像设备和分子检测平台的筹资策略带来了新的变数。供应链经理和采购主管正透过重新评估采购区域、与供应商谈判长期合约、探索本地组装以及寻找高效的二级供应商等方式来应对这些变化，以降低进口关税及相关成本波动带来的风险。

临床医生和实验室负责人正感受到这些政策变化带来的后续影响，例如试剂前置作业时间延长、影像处理硬体的资本支出增加，以及在购置成本上升的情况下，需要合理评估设备更换週期。在某些情况下，医疗系统优先投资于高通量、高性价比的平台，并透过提高检测量来分摊关税的影响。另一些医疗系统则在重新评估影像升级和分子诊断扩展之间的资金分配，力求在不影响诊断准确性的前提下，找到既能保障患者就诊又能兼顾诊断准确性的最佳方案。

重要的是，关税动态的累积影响也将波及策略伙伴关係和授权模式。拥有多元化製造地和区域分销网络的公司将更有利于维持业务连续性，而规模较小的供应商将被迫采取适应性定价策略和在地化支援模式。因此，决策者必须将贸易政策敏感性分析纳入其采购和产品蓝图，以维持营运韧性并确保诊断服务的连续性。

精细化的细分洞察揭示了疾病阶段、诊疗环境、检测架构和显像模式如何驱动诊断应用模式和投资重点。

基于细分市场的洞察揭示了疾病阶段、最终用户群、检测类型和技术模式的不同需求和运作模式。就疾病阶段而言，晚期流程着重于确诊检测和分子谱分析，以指导标靶治疗；而早期流程则优先考虑高灵敏度筛检方法和微创诊断，以支持治疗性介入。这种权衡导致了侵入性和非侵入性检测方式采用曲线的差异。

在所有终端使用者中，门诊护理机构和诊断中心优先考虑快速週转、便捷的样本采集以及能够支持大批量筛检和分诊的成本效益高的检测方法；医院重视全面的诊断能力，例如影像引导切片检查和整合分子病理学；而实验室则专注于检测方法的开发和检验，通常会利用新一代和临床实验生物标誌物来推进其转化研究流程。这些终端使用者的需求影响采购决策，并决定了在采购评估中哪些产品属性（例如自动化程度、通量和监管状态）会被优先考虑。

依检测类型区分，可以更清楚展现市场动态。生物标记检测可细分为基因标记和蛋白质标记物，其中基因标记包括循环肿瘤DNA检测和微型RNA检测，蛋白质标记包括甲胎蛋白（AFP）检测和脱氧皮质醇（DCP）检测。切片检查方法包括粗针穿刺切片和细针穿刺活检，每种方法在组织获取和併发症风险方面各有优劣。基因检测技术涵盖次世代定序和PCR分析，在覆盖范围和周转时间方面各有不同。成像技术包括CT、MRI、PET和超音波，每种技术在病灶检测、分期和治疗方案製定方面都各具优势。综合以上细分，我们可以得出结论：投资于临床检验、工作流程整合和与支付方的合作，将带来最大的临床和商业性效益。

最后，基于技术的细分不仅反映了检测类别，更突出了特定检测方式的应用促进要素：超音波具有便携性和成本效益，适用于筛检；CT 和 MRI 提供横断面细节信息，适用于分期；PET 则有助于代谢特征分析，从而改进分期和治疗反应评估。将产品设计和证据产生与这些细分需求相匹配的策略性倡议，将提高临床应用和在各种医疗机构中持续使用的可能性。

区域动态比较显示，医疗基础设施、报销管道和产能投资如何影响全球主要市场的诊断普及。

区域动态呈现出显着的异质性，这取决于医疗基础设施、法律规范、报销机制和临床实践模式。在美洲，诊断生态系统强调在连网医疗系统和学术中心内快速采用创新技术，推动了三级医院和门诊诊断网路对整合分子和影像解决方案的需求。该地区在将实验室证据转化为临床实践方面通常发挥主导作用，对支持精准肿瘤学计划的先进分子倡议表现出浓厚的兴趣。

欧洲、中东和非洲的医疗技术应用环境呈现多元化的格局。虽然一些欧洲市场已建立起结构化的报销管道和集中式参考实验室，从而促进了已验证检测方法的标准化实施，但该地区其他部分仍面临着医疗资源分配不均和资源匮乏的问题。中东和非洲的医疗卫生系统正加大对诊断能力建设的投入，旨在扩展影像基础设施和实验室，使其能够同时进行传统生物标记检测和新兴分子检测。

亚太地区的特点是基础设施投资快速成长、支付模式多样化，以及部分市场拥有强大的本土製造能力。大都会圈的大型出版中心推动了对高解析度影像检查和先进基因组检测的需求，而专注于早期检测的区域性计画则加速了非侵入性生物标记的应用。在所有地区，跨境合作进行临床检验和多中心研究正成为一种切实可行的机制，为更广泛的应用和监管协调提供必要的证据。

动态与伙伴关係动态表明，整合的产品组合、强大的实证策略和稳健的供应链将决定企业在诊断市场的长期地位。

肝癌诊断领域的竞争动态由成熟的诊断试剂製造商、专注于分子诊断的公司、影像设备供应商和临床实验室网路共同构成。市场领导凭藉其丰富的影像硬体、检测试剂套件和整合软体解决方案，保持差异化优势，这些解决方案有助于数据解读和工作流程整合。中型企业和创新新兴企业则致力于开发特色检测方法、新一代定序应用和微创生物标记组合，以满足早期检测和分子分型方面尚未满足的需求。

诊断试剂开发人员与学术中心之间的策略伙伴关係能够加速临床检验，并支持生成指南纳入所需的真实世界证据。投资于全面的临床医生教育、卫生经济学资料以及与支付方沟通的公司在实施速度方面具有优势。此外，能够提供包括样本物流、集中检测服务和结果解读彙报在内的端到端解决方案的供应商，对于寻求最大限度减轻内部营运负担的医院系统和诊断中心而言，也越来越具有吸引力。

供应链韧性、监管准备和生产规模化能力仍然是关键的差异化因素。能够扩大试剂生产规模、在多个地区获得监管批准并在临床中心维持服务网络的企业，更有可能赢得临床伙伴关係以及与医疗系统签订长期合约。产品团队和商业领导者亟需将证据产生策略与临床工作流程整合以及支付管道结合，将技术优势转化为持续的临床应用。

为产品、临床和商业团队制定可执行的策略重点，以加速产品推广、降低供应风险并展现持续的临床价值。

产业领导者应优先考虑制定一套协调一致的策略，将产品开发、临床证据产生和市场推广模式有机结合，以最大限度地提高临床应用率和商业性吸引力。投资于前瞻性研究，以证实其在早期检测和治疗分层方面的临床效用，将对指南的采纳和支付方的支持产生重大影响。同时，他们也应制定针对门诊、诊断中心、医院和研发机构的实施蓝图，以确保解决方案能够根据各机构的实际情况进行最佳化。

在营运方面，建立灵活的製造地和区域分销管道可以降低贸易成本波动带来的风险，并确保供应的连续性。与学术医疗中心和大型医院网络建立策略合作伙伴关係，可以建立参考站点，加速临床检验并促进同行采用。在商业性，采用经证实具有健康经济效益的定价模式，并提供从集中检测到床边平台等分级服务选项，可以扩大产品在各种医疗保健环境中的应用场景。

最后，领导者应投资于临床医生的教育和决策支援工具，这些工具能够将分子、蛋白质和影像数据整合到可操作的报告中。这些工具透过减少解读障碍并提供从诊断结果到治疗决策的清晰路径，缩短了应用曲线。这些工具共同作用，既能实现负责任的规模化应用，又能为患者带来具有临床意义的改进。

一项结合专家访谈、临床文献综述和技术评估的混合研究途径，检验营运和临床方面的见解。

本分析采用混合方法，整合了第一手和第二手证据，兼顾定量检验和定性背景分析。主要资料来源包括对临床专家、实验室主任、采购主管和行业高管的访谈，旨在了解实际营运和策略意图。研究观点对这些访谈内容进行了系统编码，以识别诊断方法应用、工作流程整合和支付方参与方面的共同主题。

二次研究包括对同行评审的临床文献、监管指导文件和专业学会建议进行结构化审查，以根据当前的护理标准和证据阈值提供见解。技术评估评估了分子检测、切片检查方法和成像方法的分析性能特征、平台互通性和工作流程注意事项。供应链和政策分析纳入了公开的贸易和采购讯息，以评估其对采购和资本投资决策的潜在影响。

在条件允许的情况下，我们利用多个资料流对研究结果进行三角验证，以提高其有效性。我们也承认研究存在一些局限性，例如数据可用性的区域差异以及新兴生物标记临床检验的持续发展。为了克服这些限制，我们进行了敏感度分析并举办了专家检验研讨会，以确保所提出的建议既能反映实证依据，又能兼顾在不同临床环境中实施的可行性。

总结性结论强调了在证据生成、工作流程整合和供应弹性方面的协调投资将如何塑造诊断领导。

总之，肝癌诊断格局正朝向整合式、多模态方法转变，力求在敏感度、特异性和即时操作性之间取得平衡。基因组检测和影像技术的进步不断拓展诊断套件，实现更早期的检测和更精准的分期，从而指导治疗决策。政策和采购动态，包括关税相关影响，正推动更具策略性的采购和资本规划，以确保医疗服务的可近性和营运的连续性。

细分市场分析表明，针对早期疾病和晚期疾病的不同需求，以及门诊中心、医院、诊断中心和实验室的具体营运限制，制定量身定制的策略，将最有效地推动永续推广。区域差异凸显了本地证据产生、医保报销协调和能力建构倡议的重要性。竞争对手更青睐那些整合了强大的临床检验、可扩展的生产能力和切实可行的商业模式，从而降低推广门槛的机构。

综上所述，这些主题曲折点：对实证医学、工作流程整合和供应链韧性的协调投资将决定哪些技术和供应商能够扩大规模并带来可衡量的临床效益。那些采取果断行动，优化其临床证据、商业性策略和营运准备的相关人员，将更有利于改善肝癌诊断路径和患者预后。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将循环肿瘤DNA检测整合到早期发现和监测中
  • 新兴的人工智慧影像平台增强了肝细胞癌筛检中病灶的特征分析。
  • 采用结合ctDNA、蛋白质体学和甲基化标记的多体学液态生物检体方案
  • 扩大非侵入性呼吸诊断检测在肝癌中检测挥发性有机化合物的应用
  • 将照护现场超音波弹性成像技术引入以地区为基础肝癌监测项目
  • 实施整合放射组学和基因组学的预测分析，以实现个人化监测通讯协定
  • 开发包含 AFP-L3、DCP 和一种新型凝集素检测方法的醣蛋白生物标记组合

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

第八章 肝癌诊断市场（依疾病分期划分）

  • 晚期
  • 早期的

第九章 肝癌诊断市场（依最终用户划分）

  • 门诊治疗
  • 诊断中心
  • 医院
  • 研究所

第十章 肝癌诊断市场（依检测类型划分）

  • 生物标誌物
    • 遗传标记
      • ctDNA检测
      • 微型RNA检测
    • 蛋白质标记物
      • AFP侦测
      • DCP 检查
  • 切片检查
    • 核心针穿刺切片
    • 细针穿刺法
  • 基因检测
    • 下一代定序
    • PCR分析
  • 影像
    • CT
    • MRI
    • PET
    • 超音波

第十一章 肝癌诊断市场（依技术划分）

  • CT
  • MRI
  • PET
  • 超音波

第十二章 各地区肝癌诊断市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 肝癌诊断市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国肝癌诊断市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • F. Hoffmann-La Roche Ltd.
    • Abbott Laboratories
    • Danaher Corporation
    • Siemens Healthineers AG
    • Thermo Fisher Scientific Inc.
    • bioMerieux SA
    • Hologic, Inc.
    • QIAGEN NV
    • Sysmex Corporation
    • Illumina, Inc.
Product Code: MRR-3A2E844FE71E

The Liver Cancer Diagnostics Market is projected to grow by USD 16.97 billion at a CAGR of 6.76% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 10.05 billion
Estimated Year [2025] USD 10.73 billion
Forecast Year [2032] USD 16.97 billion
CAGR (%) 6.76%

A concise overview of the shifting clinical, technological, and policy drivers that are redefining diagnostic pathways and stakeholder priorities in liver cancer care

The landscape of liver cancer diagnostics is undergoing rapid evolution driven by technological innovation, clinical practice changes, and shifting policy dynamics. This executive summary distills the most consequential developments shaping diagnosis pathways, diagnostic modality adoption, and stakeholder decision-making. The following pages synthesize clinical trends, regulatory influences, technology maturation, and operational constraints that together define the competitive and clinical milieu for diagnostic stakeholders.

The intent of this analysis is to provide an actionable synthesis that supports strategic planning across product development, commercial operations, and health system adoption. Emphasis is placed on how multi-modal diagnostic approaches are being integrated into care pathways, where evidence generation is accelerating uptake, and how payer considerations are influencing provider implementation. This section establishes the foundation for deeper insights, highlighting the interplay between diagnostic sensitivity and specificity requirements, the need for minimally invasive testing, and the push for earlier detection to enable curative-intent interventions.

Throughout the report, we prioritize clarity and relevance for leaders responsible for clinical strategy, regulatory affairs, reimbursement planning, and commercial deployment. Transitional commentary connects trends in biomarker science and imaging technology with pragmatic considerations in laboratory operations and ambulatory diagnostics, setting the stage for the more detailed thematic and regional analyses that follow.

How converging innovations in molecular diagnostics, imaging resolution, and payer-friendly evidence generation are transforming liver cancer diagnostic pathways

A confluence of transformative shifts is reshaping how liver cancer is detected, characterized, and managed. Advancements in molecular diagnostics and high-sensitivity imaging are enabling clinicians to move earlier in the disease course, improving the granularity of tumor characterization while reducing reliance on highly invasive procedures. Concurrently, the integration of circulating tumor DNA and microRNA assays with established protein markers is fostering hybrid diagnostic strategies that balance sensitivity with operational feasibility in diverse care settings.

Regulatory and reimbursement frameworks are adapting to evidence generated by real-world data and prospective validation studies, which in turn accelerates adoption when clinical utility is demonstrated. Healthcare providers are increasingly adopting multi-disciplinary diagnostic algorithms that leverage imaging modalities in parallel with targeted biomarker panels to support treatment stratification. This shift is complemented by laboratory workflow innovations and decentralized testing models that expand access in ambulatory care and diagnostic center environments.

Finally, technological convergence-where next-generation sequencing platforms, advanced bioinformatics, and higher-resolution imaging intersect-creates pathways for precision diagnostics that inform individualized therapeutic choices. These shifts collectively reduce diagnostic uncertainty, shorten time to definitive diagnosis, and generate more actionable data for oncologists, interventional radiologists, and multidisciplinary tumor boards.

Assessing how recent tariff adjustments are reshaping procurement strategies, supplier selection, and capital allocation decisions across diagnostic services and technologies

The introduction of tariffs and trade policy adjustments in 2025 has introduced new variables into procurement strategies for diagnostic consumables, imaging equipment, and molecular testing platforms. Supply chain managers and procurement leads are responding by reassessing sourcing geographies, negotiating longer-term supplier agreements, and exploring local assembly or validated secondary suppliers to mitigate exposure to import duties and associated cost volatility.

Clinicians and laboratory directors are experiencing the downstream effects of these policy changes through altered lead times for reagents, increased capital expenditure considerations for imaging hardware, and the need to justify equipment replacement cycles against a backdrop of elevated acquisition costs. In some cases, health systems are prioritizing investments in high-throughput, cost-efficient platforms that amortize tariff impacts over larger testing volumes. Others are re-evaluating capital allocation between imaging upgrades and molecular diagnostic expansion, seeking the optimal mix to sustain patient access without compromising diagnostic fidelity.

Importantly, the cumulative impact of tariff dynamics also influences strategic partnerships and licensing models. Firms with diversified manufacturing footprints and regional distribution hubs are better positioned to maintain continuity, while smaller vendors are compelled to adopt adaptive pricing strategies or localized support models. Decision-makers must therefore incorporate trade policy sensitivity analyses into procurement and product roadmaps to preserve operational resilience and maintain continuity of diagnostic services.

Granular segmentation insights reveal how disease stage, care setting, test architecture, and imaging modality collectively determine diagnostic adoption patterns and investment priorities

Segmentation-driven insight reveals distinct demand and operational patterns across disease stage, end-user profiles, test types, and technology modalities. When considering disease stage, advanced-stage workflows emphasize confirmatory testing and molecular profiling to inform targeted therapies, whereas early-stage pathways prioritize high-sensitivity screening approaches and minimally invasive diagnostics that support curative interventions. This dichotomy drives differential adoption curves for invasive versus noninvasive modalities.

Across end users, ambulatory care settings and diagnostic centers prioritize rapid turnaround, ease of sample collection, and cost-effective assays to support high-volume screening and triage; hospitals emphasize comprehensive diagnostic capabilities including image-guided biopsies and integrated molecular pathology; research laboratories focus on assay development and validation, often leveraging next-generation sequencing and investigational biomarkers to advance translational pipelines. These end-user imperatives shape procurement decisions and influence which product attributes-such as automation, throughput, and regulatory status-are prioritized in purchasing evaluations.

Test-type differentiation further clarifies market dynamics. Biomarker testing subdivides into genetic markers and protein markers, with genetic markers comprising circulating tumor DNA tests and microRNA assays, and protein markers encompassing AFP tests and DCP assays. Biopsy modalities include core needle biopsy and fine needle aspiration, each with trade-offs in tissue yield and complication risk. Genetic testing techniques span next-generation sequencing and PCR analysis, offering distinct profiles in breadth of coverage and turnaround. Imaging technologies include CT, MRI, PET, and ultrasound, with each modality delivering unique strengths in lesion detection, staging, and treatment planning. Taken together, these layered segmentation dimensions inform where investment in clinical validation, workflow integration, and payor engagement will yield the highest clinical and commercial impact.

Finally, technology-based segmentation mirrors testing categories but highlights modality-specific adoption drivers: ultrasound offers portability and cost-efficiency for screening, CT and MRI provide cross-sectional detail for staging, and PET contributes metabolic characterization that refines staging and therapeutic response assessment. Strategic initiatives that align product design and evidence generation with these segmented needs increase the likelihood of clinical adoption and sustained utilization across care settings.

Comparative regional dynamics demonstrate how healthcare infrastructure, reimbursement pathways, and capacity investments are shaping diagnostic adoption across major global markets

Regional dynamics exhibit meaningful heterogeneity driven by healthcare infrastructure, regulatory frameworks, reimbursement mechanisms, and clinical practice patterns. In the Americas, diagnostic ecosystems emphasize rapid innovation adoption within networked health systems and academic centers, fueling demand for integrated molecular and imaging solutions in tertiary hospitals and ambulatory diagnostic networks. This region often leads in the translation of clinical trial evidence into practice and demonstrates a strong appetite for advanced molecular profiling to support precision oncology initiatives.

Europe, Middle East & Africa presents a mosaic of adoption environments. Certain European markets demonstrate structured reimbursement pathways and centralized reference laboratories that facilitate standardized implementation of validated assays, while other geographies within the region contend with variability in access and resource constraints. Middle Eastern and African health systems are increasingly investing in diagnostic capacity building, with targeted initiatives to expand imaging infrastructure and laboratory capabilities that can accommodate both conventional biomarkers and emerging molecular assays.

Asia-Pacific is characterized by rapid infrastructure investment, diverse payer models, and strong domestic manufacturing capacities in select markets. High-capacity referral centers in major metropolitan areas drive demand for both high-resolution imaging and advanced genomic testing, while regional programs focused on early detection are accelerating uptake of noninvasive biomarkers. Across all regions, cross-border collaboration in clinical validation and multi-center studies is becoming a practical mechanism to generate the evidence needed for broader adoption and regulatory alignment.

Competitive and partnership dynamics reveal that integrated portfolios, robust evidence strategies, and supply chain resilience determine long-term positioning in diagnostic markets

Competitive dynamics in liver cancer diagnostics are defined by a mix of established diagnostic manufacturers, specialized molecular diagnostics firms, imaging vendors, and clinical laboratory networks. Market leaders sustain differentiated positions through broad portfolios that span imaging hardware, assay kits, and integrated software solutions that facilitate data interpretation and workflow integration. Mid-sized firms and innovative start-ups contribute by advancing niche assays, next-generation sequencing applications, and minimally invasive biomarker panels that address unmet needs in early detection and molecular subtyping.

Strategic partnerships between diagnostic developers and academic centers accelerate clinical validation and support the generation of real-world evidence necessary for guideline inclusion. Companies that invest in comprehensive clinician education, health economic dossiers, and payer engagement accrue advantages in adoption speed. Additionally, vendors that provide end-to-end solutions-encompassing sample logistics, centralized testing services, and interpretive reporting-are increasingly attractive to hospital systems and diagnostic centers seeking to minimize internal operational burden.

Supply chain resilience, regulatory preparedness, and scalability of manufacturing remain critical differentiators. Organizations that demonstrate the ability to scale reagent production, secure multi-regional regulatory clearances, and maintain service networks in clinical settings are better positioned to capture clinical partnerships and long-term contracts with health systems. For product teams and commercial leaders, the imperative is to align evidence-generation strategies with clinical workflow integration and payer pathways to translate technological advantage into durable clinical adoption.

Actionable strategic priorities for product, clinical, and commercial teams to accelerate adoption, mitigate supply risks, and demonstrate sustained clinical value

Industry leaders should prioritize a cohesive strategy that aligns product development, clinical evidence generation, and go-to-market models to maximize clinical uptake and commercial traction. Investing in prospective studies that demonstrate clinical utility in early-stage detection and treatment stratification will materially influence guideline adoption and payer support. Concurrently, companies should develop implementation roadmaps tailored to ambulatory care, diagnostic centers, hospitals, and research laboratories to ensure solutions are optimized for the operational realities of each setting.

Operationally, building flexible manufacturing footprints and regional distribution channels reduces exposure to trade-related cost fluctuations and ensures continuity of supply. Strategic collaborations with academic medical centers and large hospital networks accelerate clinical validation and create reference sites that catalyze peer adoption. On the commercial front, aligning pricing models with demonstrated health economic benefits and offering tiered service options-ranging from centralized testing to near-patient platforms-can expand addressable use cases across diverse care settings.

Finally, leaders should invest in clinician-facing education and decision-support tools that integrate molecular, protein, and imaging data into actionable reports. These tools shorten the adoption curve by reducing interpretation friction and demonstrating clear pathways from diagnostic output to therapeutic decision. Taken together, these actions will enable organizations to scale responsibly while delivering clinically meaningful improvements in patient pathways.

A mixed-methods research approach combining expert interviews, clinical literature synthesis, and technology assessments to validate operational and clinical insights

This analysis synthesizes primary and secondary evidence sources using a mixed-methods approach that balances quantitative validation with qualitative contextualization. Primary inputs include interviews with clinical experts, laboratory directors, procurement leads, and industry executives to capture operational realities and strategic intent. These perspectives were systematically coded to identify recurring themes in diagnostic adoption, workflow integration, and payer engagement.

Secondary research involved a structured review of peer-reviewed clinical literature, regulatory guidance documents, and professional society recommendations to ground insights in current standards of care and evidence thresholds. Technology assessments evaluated analytic performance characteristics, platform interoperability, and workflow considerations for molecular assays, biopsy techniques, and imaging modalities. Supply chain and policy analyses incorporated publicly available trade and procurement information to assess potential impacts on sourcing and capital investment decisions.

Where possible, findings were triangulated across multiple data streams to enhance validity. Limitations are acknowledged, including variability in regional data availability and the evolving nature of clinical validation for emerging biomarkers. To mitigate these constraints, sensitivity analyses and expert validation workshops were employed, ensuring the recommendations reflect both empirical evidence and practical feasibility for implementation across varied care settings.

Concluding synthesis emphasizing how coordinated investment in evidence generation, workflow integration, and supply resilience will shape diagnostic leadership

In summary, the diagnostic landscape for liver cancer is transitioning toward integrated, multi-modal approaches that balance sensitivity, specificity, and operational feasibility across care settings. Technological advances in genomic assays and imaging continue to expand the diagnostic toolkit, enabling earlier detection and more precise staging that inform therapeutic decision-making. Policy and procurement dynamics, including tariff-related effects, are prompting more strategic sourcing and capital planning to preserve access and operational continuity.

Segmentation analyses indicate that tailored strategies addressing the distinct needs of early versus advanced disease stages, and the specific operational constraints of ambulatory centers, hospitals, diagnostic centers, and research labs, will drive the most sustainable adoption. Regional differences underscore the importance of localized evidence generation, reimbursement alignment, and capacity-building initiatives. Competitive trajectories favor organizations that integrate robust clinical validation, scalable manufacturing, and pragmatic commercial models that lower barriers to adoption.

Collectively, these themes point to an inflection point where coordinated investment in evidence, workflow integration, and supply chain resilience will determine which technologies and providers deliver measurable clinical benefit at scale. Stakeholders that act decisively to align clinical evidence, commercial strategy, and operational readiness will be best positioned to improve diagnostic pathways and patient outcomes in liver cancer.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of circulating tumor DNA assays for early detection and monitoring
  • 5.2. Emergence of AI-enabled imaging platforms for enhanced lesion characterization in HCC screening
  • 5.3. Adoption of multi-omic liquid biopsy panels combining ctDNA, proteomics and methylation markers
  • 5.4. Expansion of non-invasive breath diagnostic tests detecting volatile organic compounds in liver cancer
  • 5.5. Incorporation of point-of-care ultrasound elastography into community-based liver cancer surveillance programs
  • 5.6. Implementation of predictive analytics integrating radiomics and genomics for personalized surveillance protocols
  • 5.7. Development of glycoprotein biomarker panels including AFP-L3, DCP and novel lectin-based assays

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Liver Cancer Diagnostics Market, by Disease Stage

  • 8.1. Advanced Stage
  • 8.2. Early Stage

9. Liver Cancer Diagnostics Market, by End User

  • 9.1. Ambulatory Care
  • 9.2. Diagnostic Centers
  • 9.3. Hospitals
  • 9.4. Research Laboratories

10. Liver Cancer Diagnostics Market, by Test Type

  • 10.1. Biomarkers
    • 10.1.1. Genetic Markers
      • 10.1.1.1. ctDNA Tests
      • 10.1.1.2. MicroRNA Tests
    • 10.1.2. Protein Markers
      • 10.1.2.1. AFP Tests
      • 10.1.2.2. DCP Tests
  • 10.2. Biopsy
    • 10.2.1. Core Needle Biopsy
    • 10.2.2. Fine Needle Aspiration
  • 10.3. Genetic Testing
    • 10.3.1. Next-Generation Sequencing
    • 10.3.2. PCR Analysis
  • 10.4. Imaging
    • 10.4.1. CT
    • 10.4.2. MRI
    • 10.4.3. PET
    • 10.4.4. Ultrasound

11. Liver Cancer Diagnostics Market, by Technology

  • 11.1. CT
  • 11.2. MRI
  • 11.3. PET
  • 11.4. Ultrasound

12. Liver Cancer Diagnostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Liver Cancer Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Liver Cancer Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. F. Hoffmann-La Roche Ltd.
    • 15.3.2. Abbott Laboratories
    • 15.3.3. Danaher Corporation
    • 15.3.4. Siemens Healthineers AG
    • 15.3.5. Thermo Fisher Scientific Inc.
    • 15.3.6. bioMerieux SA
    • 15.3.7. Hologic, Inc.
    • 15.3.8. QIAGEN N.V.
    • 15.3.9. Sysmex Corporation
    • 15.3.10. Illumina, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. LIVER CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. LIVER CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. LIVER CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ADVANCED STAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ADVANCED STAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ADVANCED STAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ADVANCED STAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY EARLY STAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY EARLY STAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY EARLY STAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY EARLY STAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY EARLY STAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CTDNA TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CTDNA TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CTDNA TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CTDNA TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CTDNA TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CTDNA TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MICRORNA TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MICRORNA TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MICRORNA TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MICRORNA TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MICRORNA TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MICRORNA TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AFP TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AFP TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AFP TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AFP TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AFP TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AFP TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DCP TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DCP TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DCP TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DCP TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DCP TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DCP TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CORE NEEDLE BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CORE NEEDLE BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CORE NEEDLE BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CORE NEEDLE BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CORE NEEDLE BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CORE NEEDLE BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PCR ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PCR ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PCR ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PCR ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PCR ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PCR ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 310. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST LIVER CANCER DIAGNO